US Patent

US11459305 — Processes for the preparation of uracil derivatives

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2028-11-07 · 2y remaining

Vulnerability score 83/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects processes and intermediates for preparing GnRH receptor antagonists and their stereoisomers and pharmaceutically acceptable salts.

USPTO Abstract

The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2842`	—

Patent Metadata

Patent number: US11459305
Jurisdiction: US
Classification: Method of Use
Expires: 2028-11-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Neurocrine Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.